Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL1256391

PIRFENIDONE
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
Cc1ccc(=O)n(-c2ccccc2)c1

Basic Information

ChEMBL ID CHEMBL1256391
Name PIRFENIDONE
Phase Approved
Structure Type MOL
InChI Key ISWRGOKTTBVCFA-UHFFFAOYSA-N
Therapeutic ✓ Yes

Known Names

AMR-69 Esbriet NSC-748456 Pirespa Pirfenidona Pirfenidone Pirfenidone axunio (previously pirfenidone aet) Pirfenidone component of esbriet Pirfenidone viatris
2
Targets
8
Activities
1
Assay Types
20
PK Parameters
20
Publications
9
Known Names
20
Indications
1
Mechanisms

Molecular Properties

185.2
MW (Da)
2.15
ALogP
2
HBA
0
HBD
22.0
PSA (Ų)
0.67
QED
0
Ro5 Violations
1
Rot. Bonds

Drug Information

Molecule Type Small molecule
First Approval 2011
Availability Prescription
Chirality Achiral

Routes of Administration

Oral

Flags

Natural Product First in Class
USAN Stem deu-
USAN Year 1975

Extended Properties

Molecular Formula C12H11NO
MW 185.23
Aromatic Rings 2
Heavy Atoms 14
NP-Likeness -1.10

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Unknown - -

Indications

Idiopathic Pulmonary Fibrosis Immune System Diseases Lung Diseases Respiratory Tract Diseases Diabetic Foot Keloid Pneumoconiosis Pneumonia Respiratory Distress Syndrome Severe Acute Respiratory Syndrome Acute Lung Injury Alveolitis, Extrinsic Allergic Bronchiolitis Obliterans Burns Carcinoma, Squamous Cell Cardiomyopathy, Hypertrophic Glomerulosclerosis, Focal Segmental Heart Failure Leiomyoma Lung Diseases, Interstitial

ATC Classification

L04AX05
pirfenidone
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: IMMUNOSUPPRESSANTS

Activity Summary

IC50 8 meas. best 6.15

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
HFL1
CHEMBL612547
IC50 6.15 6.15 710.0 1
Transforming growth factor beta-1 proprotein/Mothers against decapentaplegic homolog 3
CHEMBL4296078
IC50 5.84 5.84 1430.0 1

Pharmacokinetic Data

Parameter Value Units Species
AUC 2722.0 ng.hr.mL-1 Rattus norvegicus
AUC 649.0 ng.hr.mL-1 Rattus norvegicus
AUC 650.0 ng.hr.mL-1 Rattus norvegicus
AUC 3463.0 ng.hr.mL-1 Rattus norvegicus
AUC 3464.0 ng.hr.mL-1 Rattus norvegicus
CL 1231.17 mL.min-1.kg-1 Homo sapiens
CL 1732.1 mL.min-1.kg-1 Rattus norvegicus
CL 53.33 mL.min-1.kg-1 Rattus norvegicus
Cmax 5506.67 nM Rattus norvegicus
Cmax 5436.48 nM Rattus norvegicus
Cmax 27387.57 nM Rattus norvegicus
F 107.0 % Rattus norvegicus
T1/2 3.0 hr Homo sapiens
T1/2 1.9 hr Rattus norvegicus
T1/2 1.9 hr Rattus norvegicus
T1/2 0.096 hr Homo sapiens
T1/2 0.02433 hr Rattus norvegicus
T1/2 0.4 hr Rattus norvegicus
T1/2 0.4 hr Rattus norvegicus
Tmax 0.3 hr Rattus norvegicus

Activity Data Samples

Top measurements by pChEMBL value

Literature References

Data from ChEMBL 36 via Core Engine